Waypoint Bio Launches with $14.5M to Turbocharge Drug Discovery using in vivo Spatial Pooled Screening Technology
Company’s proprietary technology and lab-in-the-loop approach to be applied first to the discovery of novel, solid tumor cell therapies for cancers like pancreatic cancer NEW YORK – Waypoint Bio (aka “Waypoint”), a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology, today announced $14.5 million in seed funding led by Hummingbird Ventures with participation from other institutional investors, including Recode … Continue reading Waypoint Bio Launches with $14.5M to Turbocharge Drug Discovery using in vivo Spatial Pooled Screening Technology